H Lundbeck A/S (0ND5) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of H Lundbeck A/S DKK 26.92, price DKK 43.50, upside -38.1%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch H Lundbeck A/S for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
Show more
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Stock analysis
H Lundbeck A/S (0ND5) currently trades at kr 43.50, while our model-based Fair Value estimate is kr 26.92, 38.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 31.03 per share, and 0 of the 23 models we run sit above the kr 43.50 price.
Bear case: the Dividend Discount group reads lowest at kr 7.88, and 23 of the 23 models stay below the price. Evidence for this calculation is low.
Scenario range: kr 19.71 (bear) to kr 34.13 (bull), the price of kr 43.50 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Energy sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
H Lundbeck A/S reported revenue of 17.7B DKK in FY2020 versus 15.6B DKK in FY2016, a compound +3.1%/yr. Reported net income was 1.6B DKK in FY2020, compounding +6.9%/yr from FY2016.
Key figures
Market cap 32.5B DKK (≈ $4.9B) · P/S ratio 1.27 · Dividend yield 2.6% · Net margin 8.9% · Return on equity 14.9% · Return on assets (EBIT) 14.1% · Operating margin 30.3% · Revenue (TTM) 25.5B DKK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 22% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Energy peers we cover trades at −20% fair-value upside, at −38%, 0ND5 screens richer than that median.
Fair Value models
Bear kr 19.71Fair Value kr 26.92Bull kr 34.13
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.8%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.7% (2016) → 11.3% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Energy · 989 stocks
Beats the sector median on 8/11 measures
Overall it ranks above its sector peers.
Valuation
Quality Score55 · Above median
Fair Value upside−37.5% · Below median
Profitability
Return on equity (TTM)14.9% · Top 25%
Return on assets7.5% · Top 25%
Net margin (TTM)14.6% · Above median
Operating margin (TTM)30.3% · Top 25%
Growth and dividend
Revenue growth14.3% · Above median
Dividend yield (TTM)2.6% · Below median
Balance sheet
Debt / equity0.32× · Above median
Valuation Multiplesvs Energy median · lower = cheaper
P/B0.29× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM)0.19× · Cheapest 25%
EV/EBITDA1.3× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)72· sector 46
PAST (return on equity)59· sector 27
HEALTH (low debt)84· sector 88
DIVIDEND (yield)53· sector 55
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is H Lundbeck A/S (0ND5) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of kr 26.92 versus a price of kr 43.50, about −38% upside (overvalued).
What is the fair value of 0ND5?
Our model-based fair value for H Lundbeck A/S is kr 26.92 (as of Sep 23, 2026), built from audited fundamentals. The current price: kr 43.50.
What is the quality score of 0ND5?
H Lundbeck A/S has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for H Lundbeck A/S (0ND5)?
Our model-based price target is the fair value of kr 26.92 (as of Sep 23, 2026) from 23 valuation models. Cautious scenario kr 19.71, optimistic scenario kr 34.13. It is a calculation from audited fundamentals, not an analyst target.
What is the H Lundbeck A/S stock forecast for 2026?
Our models put fair value at kr 26.92, about −38% upside versus a price of kr 43.50 (overvalued). Cautious scenario kr 19.71, optimistic scenario kr 34.13. The calculation is refreshed regularly with new filings.
What is the revenue of H Lundbeck A/S (0ND5)?
H Lundbeck A/S reported trailing-twelve-month revenue of about 25.5B DKK (latest available figure, as of Sep 23, 2026).
Does H Lundbeck A/S pay a dividend?
H Lundbeck A/S currently shows a dividend yield of about 2.64% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of H Lundbeck A/S (0ND5)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For H Lundbeck A/S it is kr 26.92 per share (as of Sep 23, 2026), against a price of kr 43.50. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is H Lundbeck A/S stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 0ND5 trades above its calculated fair value: price kr 43.50, fair value kr 26.92, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0ND5?
No. The price is what the market pays today (kr 43.50); the fair value is what the company's own numbers justify (kr 26.92). For H Lundbeck A/S the two are kr 16.58 per share apart. That gap is exactly why we show both numbers side by side.
How much is H Lundbeck A/S worth?
The market values H Lundbeck A/S at about 32.5B DKK (market capitalisation, as of Sep 23, 2026). Per share that is kr 43.50; our models calculate a fair value of kr 26.92 per share.
What do the bullish and bearish scenarios say about 0ND5?
Our models span a range for H Lundbeck A/S: cautious scenario kr 19.71, base kr 26.92, optimistic kr 34.13 per share (as of Sep 23, 2026, price kr 43.50). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of H Lundbeck A/S (0ND5)?
Balance-sheet figures for H Lundbeck A/S (as of Sep 23, 2026): return on equity 14.9%, debt of 0.32 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 0ND5 from its 52-week high?
H Lundbeck A/S trades at kr 43.50, about 5% below its 52-week high of kr 45.88 and 22% above the low of kr 35.60 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 26.92 is for.
Which stocks are comparable to H Lundbeck A/S?
From the same area (Energy) we also value Saudi Arabian Oil Company, Exxon Mobil Corporation, Chevron Corporation, PetroChina Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is H Lundbeck A/S stock attractive at the current price?
The data as of Sep 23, 2026: price kr 43.50, calculated fair value kr 26.92 (−38%), Quality Score 55/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0ND5 calculated?
We run H Lundbeck A/S through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 26.92, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. H Lundbeck A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of H Lundbeck A/S (0ND5)?
The closing price on Oct 2, 2026 was kr 43.50. Our model-based fair value is kr 26.92, about −38% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with H Lundbeck A/S right now?
The price sits above even our optimistic bull case (kr 34.13). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of H Lundbeck A/S
How large is the market capitalisation of H Lundbeck A/S (0ND5)?
The market capitalisation of H Lundbeck A/S is 32.5B DKK (≈ $4.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of H Lundbeck A/S (0ND5)?
The price-to-sales ratio of H Lundbeck A/S is 1.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of H Lundbeck A/S (0ND5)?
The dividend yield of H Lundbeck A/S is 2.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of H Lundbeck A/S (0ND5)?
The net margin of H Lundbeck A/S is 8.9% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of H Lundbeck A/S (0ND5)?
The return on equity (ROE) of H Lundbeck A/S is 14.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of H Lundbeck A/S (0ND5)?
On an EBIT basis the return on assets of H Lundbeck A/S is 14.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of H Lundbeck A/S (0ND5)?
The operating margin of H Lundbeck A/S is 30.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at H Lundbeck A/S (0ND5)?
Revenue at H Lundbeck A/S is growing +14.3% versus a year earlier (3y avg +0.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at H Lundbeck A/S (0ND5)?
Earnings per share at H Lundbeck A/S are growing +47.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch H Lundbeck A/S in the live analysis
One click puts H Lundbeck A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
